News | April 25, 2017
Monsanto Statement Regarding Who Report on Glyphosate Cancer Risk
Today, the Joint FAO/WHO Meeting on Pesticide Residues (JMPR) issued a summary report on glyphosate, diazinon and malathion. The conclusions of the JMPR for glyphosate, diazinon and malathion were favorable and came to a different conclusion than IARC on all three pesticides. Concerning glyphosate specifically, Monsanto was not surprised by JMPR’s positive conclusion, which was based on all the relevant science and consistent with the findings of regulatory agencies around the world. The JMPR concluded glyphosate: presents a very low acute toxicity; is not associated with genotoxic effects in an overwhelming majority of studies conducted in mammals; and is unlikely to pose a carcinogenic risk to humans from exposure through the diet. This rigorous conclusion is based on the overwhelming weight of evidence on glyphosate and should give greater confidence to consumers around the world.
“We welcome this rigorous assessment of glyphosate by another program of the WHO, which is further evidence that this important herbicide does not cause cancer,” said Phil Miller, Monsanto’s vice president for global regulatory and government affairs. “IARC’s classification was inappropriate and inconsistent with the science on glyphosate. Based on the overwhelming weight of evidence, the JMPR has reaffirmed the findings of regulatory agencies around the world that glyphosate is unlikely to pose a cancer risk.”
Since the inconsistent and inappropriate classification of glyphosate by IARC last year, multiple regulatory agencies have again affirmed that glyphosate is not likely to cause cancer, including the European Food Safety Authority, the Canadian Pest Management Regulatory Agency and the Food Safety Commission of Japan. In addition, the October 2015 report of the U.S. EPA’s Cancer Assessment Review Committee also concluded that glyphosate is classified as “Not Likely to be Carcinogenic to Humans.”